OverviewSuggest Edit

ADC Therapeutics is a biotechnology company that focuses on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and haematological cancers. The company employs monoclonal antibodies specific to particular tumour antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine-based warheads to selectively kill cancer cells.
TypePublic
Founded2010
HQEpalinges, CH
Websiteadctherapeutics.com

Latest Updates

Employees (est.) (May 2020)116(+2%)
Job Openings21
Revenue (FY, 2018)$1.1 M(-36%)
Share Price (Sept 2021)$29(-1%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at ADC Therapeutics

Ron Squarer

Ron Squarer

Chairman
Stephen Evans-Freke

Stephen Evans-Freke

Non-Executive Director
Peter B. Corr

Peter B. Corr

Non-Executive Director
Michael Forer

Michael Forer

Vice Chairman and Executive Vice President
Richard Onyett

Richard Onyett

Vice President of Business Development
Peter Greaney

Peter Greaney

Head of Corporate Development
Show more

ADC Therapeutics Office Locations

ADC Therapeutics has offices in Epalinges, New Providence, San Mateo and Greater London
Epalinges, CH (HQ)
3B Route de la Corniche
Greater London, GB
Queen Mary Innovation Centre 42 New Rd
New Providence, NJ, US
430 Mountain Ave
San Mateo, CA, US
1510 Fashion Island Blvd #205
Show all (4)

ADC Therapeutics Financials and Metrics

ADC Therapeutics Revenue

ADC Therapeutics's revenue was reported to be $1.14 m in FY, 2018 which is a 36.8% decrease from the previous period.
USD

Net income (FY, 2020)

(246.3m)

Market capitalization (23-Sept-2021)

2.3b

Closing stock price (23-Sept-2021)

29.0

Cash (31-Dec-2020)

439.2m
ADC Therapeutics's current market capitalization is $2.3 b.
USDFY, 2017FY, 2018FY, 2020

Revenue

1.8m1.1m

Revenue growth, %

(37%)

General and administrative expense

7.9m8.8m

R&D expense

85.5m118.3m
USDFY, 2017FY, 2018FY, 2020

Cash

262.8m138.8m439.2m

Accounts Receivable

1.1m192.0k

Current Assets

265.2m142.1m450.5m

PP&E

1.1m1.5m1.6m
USDFY, 2017FY, 2018FY, 2020

Net Income

(89.9m)(123.1m)(246.3m)

Depreciation and Amortization

341.0k740.0k

Accounts Payable

5.5m(858.0k)

Cash From Operating Activities

(74.9m)(121.4m)(168.7m)
USDFY, 2017

Revenue/Employee

34.7k

Financial Leverage

1.1 x
Show all financial metrics

ADC Therapeutics Operating Metrics

Sep, 2019

Clinical Phase Products (Hematology)

3

Clinical Phase Products (Solid Tumor)

2

Preclinical Phase Products (Solid Tumor)

2
Show all operating metrics

ADC Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
ADC Therapeutics America, Inc.
ADC Therapeutics (UK) Ltd

ADC Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

SecurityScorecard logo

ADC Therapeutics Online and Social Media Presence

Embed Graph

ADC Therapeutics News and Updates

Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA ("ADCT…

Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)

Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020

New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO

VIRGINIA BEACH, Va., June 30, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfolio company, ADC Therapeutics (NYSE:ADCT). The company raised $267.6 million through...

ADC Therapeutics to offer 8.1 million shares in planned IPO, priced at $23 to $26 each

ADC Therapeutics SA set terms for its planned initial public offering on Monday, saying in a regulatory filing that it expects to offer 8.1 million shares priced at $23 to $26 each. The clinical-stage, oncology-focused biotech has applied to list on the New York Stock Exchange, under the ticker sym…

AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale

AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale

Chronic Lymphocytic Leukemia Treatment 2018 Global Market Key Players – 4SC, AbbVie, ACEA Biosciences, ADC Therapeutics, Aeglea BioTherapeutics – Analysis and Forecast to 2025

WiseGuyRerports.com Presents “Global Chronic Lymphocytic Leukemia Treatment Market Size, Status and Forecast 2018-2025” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday

ADC Therapeutics Frequently Asked Questions

  • When was ADC Therapeutics founded?

    ADC Therapeutics was founded in 2010.

  • Who are ADC Therapeutics key executives?

    ADC Therapeutics's key executives are Ron Squarer, Stephen Evans-Freke and Peter B. Corr.

  • How many employees does ADC Therapeutics have?

    ADC Therapeutics has 116 employees.

  • Who are ADC Therapeutics competitors?

    Competitors of ADC Therapeutics include Mersana Therapeutics, ImmunoGen and Immunomedics.

  • Where is ADC Therapeutics headquarters?

    ADC Therapeutics headquarters is located at 3B Route de la Corniche, Epalinges.

  • Where are ADC Therapeutics offices?

    ADC Therapeutics has offices in Epalinges, New Providence, San Mateo and Greater London.

  • How many offices does ADC Therapeutics have?

    ADC Therapeutics has 4 offices.